U.S. markets close in 5 hours 5 minutes

Sernova Corp. (SEOVF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.9925-0.0025 (-0.25%)
As of 9:37AM EDT. Market open.

Sernova Corp.

The Stiller Centre
700 Collip Circle Suite 114
London, ON N6G 4X8


IndustryMedical Devices
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Philip M. ToleikisPres, CEO & Director286.61kN/AN/A
Mr. David Swetlow C.A., CPA, C.AChief Financial Officer143.3kN/AN/A
Mr. Douglas MaretChief Science OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells or tissues for the treatment of chronic diseases, such as diabetes, hemophilia, and hypothyroid disease. The company has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected universal therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.

Corporate Governance

Sernova Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.